WHO strongly recommends antiviral drug for patients with non-severe covid-19: A combination of nirmatrelvir and ritonavir is strongly recommended for patients at highest risk of hospital admission. WHO also makes a conditional recommendation for remdesivir in the same group of patients. Pfizer’s oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) is strongly recommended […]
WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission: The antiviral drug molnupiravir is conditionally recommended for patients with non-severe covid-19 who are at highest risk of hospitalisation, says a WHO Guideline Development Group of international experts in The BMJ today. Patients who are at highest risk of hospitalisation typically […]
Read More… from WHO: Covid-19 antiviral drug molnupiravir recommendation
News Release: Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared […]
Read More… from Merck and Ridgeback’s Antiviral Molnupiravir trial